Journal of International Oncology ›› 2013, Vol. 40 ›› Issue (2): 123-126.

Previous Articles     Next Articles

Application of pemetrexed for the treatment of non-small-cell lung cancer

LI  Jun, XU  Xiang-Ying   

  1. Department of Radiation Oncology, the Third Affiliated Hospital, Harbin Medical University, Harbin 150081, China
  • Online:2013-02-08 Published:2013-01-25
  • Contact: Corresponding author: Xu Xing-ying, E-mail: xuxxyy@sohu.com E-mail:xuxxyy@sohu.com

Abstract: Pemetrexed is a novel antifolate which is approved in the USA and Europe for the treatment of non-small-cell lung cancer (NSCLC). Researches reveal that pemetrexed enhances radiation-induced cell inactivation. A series of clinical trials of pemetrexed combined with radiotherapy for NSCLC also demonstrated that pemetrexed provides similar ef?cacy with lower toxicity and better tolerability than other third-generation chemotherapy drugs.

Key words: Carcinoma, non-samll-cell lung, Radiotherapy, Pemetrexed